Key Highlights
- Revolution Medicines (RVMD) shares jumped 20% in overnight trading following groundbreaking Phase 3 data for daraxonrasib in pancreatic cancer treatment.
- The experimental drug reduced mortality risk by 60%, extending median patient survival to 13.2 months compared to 6.7 months with standard chemotherapy.
- The company has initiated a rolling New Drug Application (NDA) submission with the FDA and intends to pursue worldwide regulatory approvals.
- Meanwhile, Summit Therapeutics (SMMT) shares climbed 3.6% after ivonescimab demonstrated a 15% survival benefit over Tevimbra in lung cancer patients.
- The findings from both biotechnology firms were unveiled at Sunday’s American Society of Clinical Oncology (ASCO) conference in Chicago.
Revolution Medicines (RVMD) experienced a dramatic 20% surge in after-hours trading Sunday, maintaining a 7.3% gain at $169 during Monday’s premarket session following the release of clinical trial data that industry experts are characterizing as “unprecedented.”
Revolution Medicines, Inc., RVMD
The compelling results emerged from the company’s Phase 3 RASolute 302 clinical trial, which was featured at the ASCO Plenary Session and simultaneously published in The New England Journal of Medicine.
Patients receiving daraxonrasib achieved a median overall survival of 13.2 months — representing a near doubling compared to the 6.7-month median observed with conventional chemotherapy. This milestone marks the first time any Phase 3 clinical trial has demonstrated median survival exceeding one year in previously treated metastatic pancreatic cancer.
The international study enrolled 500 participants and evaluated the once-daily oral medication against standard chemotherapy in patients who had previously undergone at least one line of therapy.
Beyond extending overall survival, daraxonrasib demonstrated a 60% reduction in mortality risk and significantly delayed disease progression. Patients experienced a median progression-free survival of 7.2 months, more than double the 3.6-month median seen with chemotherapy alone.
Tumor response rates also favored the experimental treatment, with approximately 32% of daraxonrasib patients experiencing tumor shrinkage versus just 11% in the chemotherapy arm. The therapeutic benefit was consistent regardless of whether patients harbored detectable RAS mutations.
Additional Clinical Benefits Observed
Patients treated with daraxonrasib maintained effective control of cancer-related pain for a median duration of 9.2 months, substantially longer than the 3.8-month median in the chemotherapy group. Similarly, quality of life preservation extended to 5.7 months compared to 2.6 months with standard treatment.
The safety profile proved equally impressive. Only 1.2% of daraxonrasib recipients discontinued therapy due to adverse events, a stark contrast to the 11.2% discontinuation rate among chemotherapy patients.
Raymond James analyst Sean McCutcheon characterized the overall survival findings as a “home run” and anticipates swift and widespread clinical adoption. Multiple brokerage firms have independently described the trial outcomes as “compelling.”
Chief Executive Officer Mark Goldsmith stated the drug “redefined treatment expectations” for this challenging patient population.
Revolution Medicines has commenced a rolling NDA submission and intends to pursue regulatory approvals across multiple global markets, including submission to the FDA utilizing a Commissioner’s National Priority Voucher. The FDA has granted authorization for an expanded access protocol, enabling qualified patients to access the treatment prior to potential commercial approval.
RVMD shares have nearly doubled in value year-to-date and appreciated more than 9% throughout May.
Summit Therapeutics Reports Positive Lung Cancer Data
Summit Therapeutics (SMMT) saw shares advance 3.6% to $18.17 in premarket activity following the announcement that ivonescimab — co-developed with Chinese partner Akeso — delivered a 15% improvement in overall survival compared to Tevimbra in a direct comparative trial.
Patients with advanced squamous non-small cell lung cancer treated with ivonescimab plus chemotherapy achieved a mean survival of 27.9 months, outperforming the 23.7-month average for those receiving Tevimbra combined with chemotherapy.
The clinical study was performed in China. Summit maintains commercial rights to ivonescimab across the United States, Canada, Europe, and Japan through a licensing agreement valued at up to $5 billion.
However, some market analysts expressed reservations. Jefferies analyst Faisal Khurshid suggested investors will likely scrutinize whether these outcomes can be reproduced in global clinical trials, especially within U.S. and European patient populations.
SMMT stock has remained relatively unchanged on a year-to-date basis.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
